LEXEO THERAPEUTICS INC (LXEO) Stock Price, Quote, News and Overview
NASDAQ:LXEO - Nasdaq - US52886X1072 - Common Stock - Currency: USD
LXEO Quote, Performance and Key Statistics
3.92
-0.02 (-0.51%)
The current stock price of LXEO is 3.92 USD. In the past month the price increased by 20.99%. In the past year, price decreased by -75.8%.
LXEO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.58 | 337.14B | ||
| AMGN | AMGEN INC | 14.24 | 158.93B | ||
| GILD | GILEAD SCIENCES INC | 14.32 | 137.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.8 | 56.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.26B | ||
| ARGX | ARGENX SE - ADR | 95.86 | 33.66B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.76 | 28.60B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.56B | ||
| NTRA | NATERA INC | N/A | 22.97B | ||
| BIIB | BIOGEN INC | 8.28 | 19.20B | ||
| INSM | INSMED INC | N/A | 18.50B |
Related stock screener links
About LXEO
Company Profile
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Company Info
LEXEO THERAPEUTICS INC
345 Park Avenue South, Floor 6
New York City NEW YORK US
Employees: 69
Phone: 12125479879
LEXEO THERAPEUTICS INC / LXEO FAQ
What is the stock price of LEXEO THERAPEUTICS INC today?
The current stock price of LXEO is 3.92 USD. The price decreased by -0.51% in the last trading session.
What is the ticker symbol for LEXEO THERAPEUTICS INC stock?
The exchange symbol of LEXEO THERAPEUTICS INC is LXEO and it is listed on the Nasdaq exchange.
On which exchange is LXEO stock listed?
LXEO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LEXEO THERAPEUTICS INC stock?
13 analysts have analysed LXEO and the average price target is 19.38 USD. This implies a price increase of 394.39% is expected in the next year compared to the current price of 3.92. Check the LEXEO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LEXEO THERAPEUTICS INC worth?
LEXEO THERAPEUTICS INC (LXEO) has a market capitalization of 130.14M USD. This makes LXEO a Micro Cap stock.
How many employees does LEXEO THERAPEUTICS INC have?
LEXEO THERAPEUTICS INC (LXEO) currently has 69 employees.
What are the support and resistance levels for LEXEO THERAPEUTICS INC (LXEO) stock?
LEXEO THERAPEUTICS INC (LXEO) has a support level at 3.91 and a resistance level at 3.93. Check the full technical report for a detailed analysis of LXEO support and resistance levels.
Should I buy LEXEO THERAPEUTICS INC (LXEO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LXEO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LXEO, evaluating the profitability, health, valuation and growth aspects
- LEXEO THERAPEUTICS INC (LXEO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LEXEO THERAPEUTICS INC (LXEO) Sales and EPS estimates to see what analysts future expectations are.
- LEXEO THERAPEUTICS INC (LXEO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LEXEO THERAPEUTICS INC (LXEO) Insider and Institutional Ownership to learn about the owners and their transactions.
- LEXEO THERAPEUTICS INC (LXEO) Stock Chart to make your own analysis
- LEXEO THERAPEUTICS INC (LXEO) Latest news and press-releases to stay up to date.
Does LEXEO THERAPEUTICS INC (LXEO) stock pay dividends?
LXEO does not pay a dividend.
What is the Price/Earnings (PE) ratio of LEXEO THERAPEUTICS INC (LXEO)?
LEXEO THERAPEUTICS INC (LXEO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.3).
What is the Short Interest ratio of LEXEO THERAPEUTICS INC (LXEO) stock?
The outstanding short interest for LEXEO THERAPEUTICS INC (LXEO) is 9.8% of its float. Check the ownership tab for more information on the LXEO short interest.
LXEO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LXEO. When comparing the yearly performance of all stocks, LXEO is a bad performer in the overall market: 83.13% of all stocks are doing better.
LXEO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to LXEO. LXEO has a bad profitability rating. Also its financial health evaluation is rather negative.
LXEO Financial Highlights
Over the last trailing twelve months LXEO reported a non-GAAP Earnings per Share(EPS) of -3.3. The EPS decreased by -22.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.78% | ||
| ROE | -123.78% | ||
| Debt/Equity | 0.01 |
LXEO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to LXEO. The Buy consensus is the average rating of analysts ratings from 13 analysts.